Journal of Literature Pharmacy Sciences

Antiinflamatuar Etkinin Değerlendirilmesinde Kullanılanin vitro ve in vivo Yöntemler: Geleneksel Derleme
In vitro and in vivo Methods Used in Evaluation of Anti-Inflammatory Effect:A Traditional Review
Hilal ERDEMa,b, Zeynep DOĞANc , İclal SARAÇOĞLUb,d
aTokat Gaziosmanpaşa Üniversitesi Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmakognozi AD, Tokat, Türkiye
bHacettepe Üniversitesi Sağlık Bilimleri Enstitüsü, Farmakognozi Programı, Ankara, Türkiye
cHacettepe Üniversitesi Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmakognozi AD, Ankara, Türkiye
dLokman Hekim Üniversitesi Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmakognozi AD, Ankara, Türkiye
J Lit Pharm Sci. 2025;14(2):54-67
doi: 10.5336/pharmsci.2024-107415
Article Language: TR
Full Text
ÖZET
 İnflamasyon, canlının her türlü yaralanmaya karşı verdiği olağan bir tepkidir. Bir dizi biyokimyasal olayı içeren, hücresel hasar tarafından tetiklenen, kızarıklık, ısı artışı, şişlik, ağrı ve fonksiyon kaybı ile karakterize, karmaşık bir doku reaksiyonudur. İnflamasyonun gerçekleştiği durumda canlıda hasarlı doku onarılmakta ve yeniden şekillenmektedir. İnflamasyon, organizma tarafından zararlı uyaranları ortadan kaldırmak için alınan koruyucu bir önlem olsa da kontrolsüz olduğu durumda hasara yol açmaktadır. Kontrol altına alınamayan inflamasyon romatoid artrit, diyabet, kanser, nörodejeneratif hastalıklar (Alzheimer vb.) ve aterosklerozun yanı sıra pulmoner, otoimmün ve kardiyovasküler hastalıkların gelişmesine neden olmaktadır. İnflamasyonun kontrol altına alınması için, antiinflamatuar etkili ilaçlar kullanılmaktadır. İnflamatuar, sürece müdahale edebilen antiinflamatuar ilaçlar tedavide önemlidir. Mevcut antiinflamatuar ilaçların yan etkilerinin ve maliyetlerinin fazla olması gibi olumsuzluklar, araştırmacıları yeni alternatif ilaç araştırmalarına yönlendirmektedir. Antiinflamatuar etkili olduğu düşünülen ajanın etkisinin değerlendirilmesinde ilk aşama olarak in vitro ve ardından in vivo yöntemler sıklıkla kullanılmaktadır. İn vitro yöntemler arasında en sık sitokinlerin miktar tayini, Western Blot analizi ve hücre içi oksidatif stres tayin yöntemleri kullanılırken, in vivo yöntemlerden ise karragenan ile oluşturulmuş pençe ödemi ve kroton yağı ile oluşturulmuş kulak ödemi deney modellerinin kullanıldığı görülmektedir. Bu derlemede, genç araştırmacılara yol gösterici olacağı düşünülerek, antiinflamatuar etkinin değerlendirilmesinde kullanılan in vitro ve in vivo yöntemler ile ilgili bilgiler sunulmuştur.

Anahtar Kelimeler: İnflamasyon; antiinflamatuar ajanlar; sitokinler
ABSTRACT
 Inflammation is a normal response of an organism to any injury. It is a complex tissue reaction involving a series of biochemical events, triggered by cellular damage and characterized by redness, warmth, swelling, pain and loss of function. Damaged tissue is repaired and reshaped. When inflammation occurs, damaged tissue in a living organism is repaired and remodeled. While inflammation is a protective measure taken by the body to eliminate harmful stimuli, it can cause damage if left uncontrolled. Uncontrolled inflammation is causes of rheumatoid arthritis, diabetes, neurodegenerative diseases (Alzheimer's disease, etc), cancer and atherosclerosis, as well as pulmonary, autoimmune, and cardiovascular diseases. Anti-inflammatory drugs are used to control inflammation. Anti-inflammatory drugs that can interfere with the inflammatory process are important in treatment. Disadvantages such as the high cost and side effects of the current anti-inflammatory drugs lead researchers to search for new alternative drugs. in vitro and in vivo methods are frequently used as the first step in evaluating the effect of the agent thought to be anti-inflammatory. Among the in vitro methods, the most frequently used methods are cytokine quantification, Western Blot analysis and intracellular oxidative stress determination, while among the in vivo methods, carrageenan-induced paw edema and croton oil-induced ear edema experimental models are used. In the present review, information about in vitro and in vivo methods used in the evaluation of anti-inflammatory effect is given, considering that it will guide to young researchers.

Keywords: Inflammation; anti-inflammatory agents; cytokines
REFERENCES:
  1. Debnath T, Kim DH, Lim BO. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules. 2013;18(6):7253-70. [Crossref]  [PubMed]  [PMC] 
  2. Patil KR, Mahajan UB, Unger BS, Goyal SN, Belemkar S, Surana SJ, et al. Animal models of inflammation for screening of anti-inflammatory drugs: implications for the discovery and development of phytopharmaceuticals. Int J Mol Sci. 2019;20(18):4367. [Crossref]  [PubMed]  [PMC] 
  3. Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine. 2021;91:153712. [PubMed]  [PMC] 
  4. Gupta M, Singh N, Gulati M, Gupta R, Sudhakar K, Kapoor B. Herbal bioactives in treatment of inflammation: an overview. S Afr J Bot. 2021;143:205-25. [Link] 
  5. El Nashar HAS, Mostafa NM, Eldahshan OA, Singab ANB. A new antidiabetic and anti-inflammatory biflavonoid from Schinus polygama (Cav.) Cabrera leaves. Nat Prod Res. 2022;36(5):1182-90. [Crossref]  [PubMed] 
  6. Anosike CA, Ako AC, Nwodo OFC. Anti-inflammatory and membrane stabilization activities of methanol extract of Cissus aralioides leaves. Res J Pharm Biol Chem Sci. 2018;9(4):18-28. [Link] 
  7. Singh S, Devi B. Anti-inflammatory activity of Cucumis melo L. subsp. agrestis (Naudin) Pangalo. Int J Pharm Sci Res. 2020;11(8):3819-23. [Crossref] 
  8. Heydari H, Saltan Işcan G, Eryilmaz M, Bahadir Acikara Ö, Yilmaz Sarialtin S, Tekin M, et al. Antimicrobial and anti-inflammatory activity of some Lathyrus L. (Fabaceae) species growing in Turkey. Turk J Pharm Sci. 2019;16(2):240-5. [PubMed]  [PMC] 
  9. Sato H, Taketomi Y, Murakami M. Metabolic regulation by secreted phospholipase A2. Inflamm Regen. 2016;36:7. [PubMed]  [PMC] 
  10. Lehr M. Phospholipase A2 inhibitors in inflammation. Expert Opin Ther Pat. 2001;11 (7):1123-36. [Crossref] 
  11. Mohamed Tap F, Abd Majid FA, Ismail HF, Wong TS, Shameli K, Miyake M, et al. In Silico and in vitro study of the bromelain-phytochemical complex inhibition of phospholipase A2 (Pla2). Molecules. 2018;23(1):73. [Crossref]  [PubMed]  [PMC] 
  12. Nguyen HT, Vu TY, Chandi V, Polimati H, Tatipamula VB. Dual COX and 5-LOX inhibition by clerodane diterpenes from seeds of Polyalthia longifolia (Sonn.) Thwaites. Sci Rep. 2020;10(1):15965. [Link] 
  13. Azad R, Babu NK, Gupta AD, Reddanna P. Evaluation of anti-inflammatory and immunomodulatory effects of Premna integrifolia extracts and assay-guided isolation of a COX-2/5-LOX dual inhibitor. Fitoterapia. 2018;131:189-99. [Link] 
  14. Rajaram A, Vanaja GR, Vyakaranam P, Rachamallu A, Reddy GV, Anilkumar K, et al. Anti-inflammatory profile of Aegle marmelos (L) Correa (Bilva) with special reference to young roots grown in different parts of India. J Ayurveda Integr Med. 2018;9(2):90-8. [PubMed]  [PMC] 
  15. Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp). 2012;2(2):103-11. [Crossref]  [PubMed]  [PMC] 
  16. Ding X, Qamar A, Liu H. The complement system testing in clinical laboratory. Clin Chim Acta. 2023;541:117238. [PubMed] 
  17. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171(3):715-27. [Crossref]  [PubMed]  [PMC] 
  18. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227-35. [PubMed]  [PMC] 
  19. Moon HI, Jung S, Lee YC, Lee JH. Anticomplement activity of isolated compounds from Artemisia montana. Immunopharmacol Immunotoxicol. 2012;34(1):113-5. [Crossref]  [PubMed] 
  20. Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Molecular pharmacology of inflammation: medicinal plants as anti-inflammatory agents. Pharmacol Res. 2019;139:126-40. [Crossref]  [PubMed] 
  21. Xu J, Zhao Y, Aisa HA. Anti-inflammatory effect of pomegranate flower in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. Pharm Biol. 2017;55(1):2095-101. [Crossref]  [PubMed]  [PMC] 
  22. Song MY, Jung HW, Kang SY, Kim KH, Park YK. Anti-inflammatory effect of Lycii radicis in LPS-stimulated RAW 264.7 macrophages. Am J Chin Med. 2014;42(4):891-904. [PubMed] 
  23. Zargar OA, Bashir R, Ganie SA, Hamid R. The effect of Elsholtzia densa methanolic extract modulates inflammation in vitro and in vivo. Orient Pharm Exp Med. 2019;19(1):49-58. [Crossref] 
  24. Dogan Z, Telli G, Tel BC, Saracoglu I. Scutellaria brevibracteata Stapf and active principles with anti-inflammatory effects through regulation of NF-κB/COX-2/iNOS pathways. Fitoterapia. 2022;158:105159. [Crossref]  [PubMed] 
  25. Özbilgin S, Küpeli Akkol E, Süntar I, Tekin M, Saltan İşcan G. Wound-healing activity of some species of Euphorbia L. Rec Nat Prod. 2018;13(2):104-13. [Link] 
  26. Kumar A, Kour G, Chibber P, Saroch D, Kumar C, Ahmed Z. Novel alantolactone derivative AL-04 exhibits potential anti-inflammatory activity via modulation of iNOS, COX-2 and NF-κB. Cytokine. 2022;158:155978. [PubMed] 
  27. Abdel Maksoud MS, El Gamal MI, Gamal El Din MM, Choi Y, Choi J, Shin JS, et al. Synthesis of new triarylpyrazole derivatives possessing terminal sulfonamide moiety and their inhibitory effects on PGE₂ and nitric oxide productions in lipopolysaccharide-induced RAW 264.7 macrophages. Molecules. 2018;23(10):2556. [PubMed]  [PMC] 
  28. Achoui M, Appleton D, Abdulla MA, Awang K, Mohd MA, Mustafa MR. In vitro and in vivo anti-inflammatory activity of 17-O-acetylacuminolide through the inhibition of cytokines, NF-κB translocation and IKKβ activity. PLoS One. 2010;5(12):e15105. [Crossref]  [PubMed]  [PMC] 
  29. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204-18. [Crossref]  [PubMed]  [PMC] 
  30. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537-49. [Crossref]  [PubMed] 
  31. Lu N, Malemud CJ. Extracellular signal-regulated kinase: a regulator of cell growth, inflammation, chondrocyte and bone cell receptor-mediated gene expression. Int J Mol Sci. 2019;20(15):3792. [PubMed]  [PMC] 
  32. Zhang CH, Sheng JQ, Sarsaiya S, Shu FX, Liu TT, Tu XY, et al. The anti-diabetic activities, gut microbiota composition, the anti-inflammatory effects of Scutellaria-coptis herb couple against insulin resistance-model of diabetes involving the toll-like receptor 4 signaling pathway. J Ethnopharmacol. 2019;237:202-14. [PubMed] 
  33. Chen YX, Zhang XQ, Yu CG, Huang SL, Xie Y, Dou XT, et al. Artesunate exerts protective effects against ulcerative colitis via suppressing Toll‑like receptor 4 and its downstream nuclear factor‑κB signaling pathways. Mol Med Rep. 2019;20(2):1321-32. [PubMed]  [PMC] 
  34. Gao H, Kang N, Hu C, Zhang Z, Xu Q, Liu Y, et al. Ginsenoside Rb1 exerts anti-inflammatory effects in vitro and in vivo by modulating toll-like receptor 4 dimerization and NF-kB/MAPKs signaling pathways. Phytomedicine. 2020;69:153197. [PubMed] 
  35. Jalali M, Zaborowska J, Jalali M. The polymerase chain reaction: PCR, qPCR and RT-PCR. In Basic Science Methods for Clinical Researchers. 1st ed. London: Academic Press; 2016. p.1-15. [Crossref]  [PubMed] 
  36. Dymond JS. Explanatory chapter: quantitative PCR. Methods Enzymol. 2013;529:279-89. [PubMed] 
  37. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc. 2006;1(3):1559-82. [PubMed] 
  38. Chatterjee S. Oxidative stress inflammation and disease. Dziubla T, Butterfield A. Oxidative Stress and Biomaterials. 1st ed. London: Academic Press.; 2016. p.35-58. [Crossref]  [PubMed] 
  39. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19. [Crossref]  [PubMed]  [PMC] 
  40. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: a review. Eur J Med Chem. 2015;97:55-74. [Crossref]  [PubMed] 
  41. Shahreza FD. Oxidative stress, free radicals, kidney disease and plant antioxidants. Immunopathol Persa. 2017;3(2):e11. [Crossref]  [PubMed] 
  42. Ighodaro OM, Akinloye O. A. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alex J Med. 2018;54(4):287-93. [Link] 
  43. Yilgor A, Demir C. Determination of oxidative stress level and some antioxidant activities in refractory epilepsy patients. Sci Rep. 2024;14(1):6688. [Crossref]  [PubMed]  [PMC] 
  44. Cordiano R, Di Gioacchino M, Mangifesta R, Panzera C, Gangemi S, Minciullo PL. Malondialdehyde as a potential oxidative stress marker for allergy-oriented diseases: an update. Molecules. 2023;28(16):5979. [Crossref]  [PubMed]  [PMC] 
  45. Krishna H, Avinash K, Shivakumar A, Al Tayar NGS, Shrestha AK. A quantitative method for the detection and validation of catalase activity at physiological concentration in human serum, plasma and erythrocytes. Spectrochim Acta A Mol Biomol Spectrosc. 2021;251:119358. [Crossref]  [PubMed] 
  46. Mei S, Song X, Wang Y, Wang J, Su S, Zhu J, et al. Studies on protection of astaxanthin from oxidative damage induced by H2O2 in RAW 264.7 cells based on 1H NMR metabolomics. J Agric Food Chem. 2019;67(49):13568-76. [Crossref]  [PubMed] 
  47. Zhang L, Zhang H, Li X, Jia B, Yang Y, Zhou P, et al. Miltirone protects human EA.hy926 endothelial cells from oxidized low-density lipoprotein-derived oxidative stress via a heme oxygenase-1 and MAPK/Nrf2 dependent pathway. Phytomedicine. 2016;23(14):1806-13. [Crossref]  [PubMed] 
  48. Su J, Zhang X, Kan Q, Chu X. Antioxidant activity of acanthopanax senticosus flavonoids in H2O2-induced RAW 264.7 cells and dss-induced colitis in mice. Molecules. 2022;27(9):2872. [Crossref]  [PubMed]  [PMC] 
  49. Zhang X, Retyunskiy V, Qiao S, Zhao Y, Tzeng CM. Alloferon-1 ameliorates acute inflammatory responses in λ-carrageenan-induced paw edema in mice. Sci Rep. 2022;12(1):16689. [Crossref]  [PubMed]  [PMC] 
  50. Karim N, Khan I, Khan W, Khan I, Khan A, Halim SA, et al. Anti-nociceptive and anti-inflammatory activities of asparacosin a involve selective cyclooxygenase 2 and inflammatory cytokines inhibition: an in-vitro, in-vivo, and in-silico approach. Front Immunol. 2019;10:581. [Crossref]  [PubMed]  [PMC] 
  51. Bidian C, Filip GA, David L, Moldovan B, Baldea I, Olteanu D, et al. Viburnum opulus fruit extract-capped gold nanoparticles attenuated oxidative stress and acute inflammation in carrageenan-induced paw edema model. GCLR. 2022;15(2):319-35. [Crossref]  [PubMed] 
  52. Sarkhel S. Evaluation of the anti-inflammatory activities of Quillaja saponaria Mol. saponin extract in mice. Toxicol Rep. 2015;3:1-3. [Crossref]  [PubMed]  [PMC] 
  53. Ben IO, Gamey LE, Harley BK, Agyei PEO, Woode E. Effect of Trichilia monadelpha (Thonn.) J. J. de Wilde (Meliaceae) extracts on C-reactive proteins levels and acute inflammation. Sci Afr. 2022;16:e01119. [Crossref]  [PubMed] 
  54. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of histamine in modulating the immune response and inflammation. Mediators inflamm. 2018;2018:9524075. [Crossref]  [PubMed]  [PMC] 
  55. Pirahanchi Y, Sharma S. Physiology, Bradykinin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: [Link] 
  56. Patel MMurugananthan, Shivalinge Gowda KP. In vivo animal models in preclinical evaluation of antiinflammatory activity-A review. IJPRAS. 2012;1(2):1-5. [Link] 
  57. Rachmawati H, Safitri D, Pradana AT, Adnyana IK. TPGS-stabilized curcumin nanoparticles exhibit superior effect on carrageenan-induced inflammation in Wistar Rat. Pharmaceutics. 2016;8(3):24. [Crossref]  [PubMed]  [PMC] 
  58. Leitão MM, Radai JAS, Ferrari IC, Negrão FJ, Silva Filho SE, Oliveira RJ, et al. Effects of an ethanolic extract and fractions from Piper glabratum (Piperaceae) leaves on pain and inflammation. Regul Toxicol Pharmacol. 2020;117:104762. [Crossref]  [PubMed] 
  59. Sadeghi H, Parishani M, Akbartabar Touri M, Ghavamzadeh M, Jafari Barmak M, Zarezade V, et al. Pramipexole reduces inflammation in the experimental animal models of inflammation. Immunopharmacol Immunotoxicol. 2017;39(2):80-6. [Crossref]  [PubMed] 
  60. Tubaro A, Dri P, Delbello G, Zilli C, Della Loggia R. The croton oil ear test revisited. Agents Actions. 1986;17(3-4):347-9. [Crossref]  [PubMed] 
  61. Camponogara C, Casoti R, Brusco I, Piana M, Boligon AA, Cabrini DA, et al. Tabernaemontana catharinensis leaves exhibit topical anti-inflammatory activity without causing toxicity. J Ethnopharmacol. 2019;231:205-16. [Crossref]  [PubMed] 
  62. Hijazy HHA, Dahran N, Althagafi HA, Alharthi F, Habotta OA, Oyouni AAA, et al. Thymoquinone counteracts oxidative and inflammatory machinery in carrageenan-induced murine paw edema model. Environ Sci Pollut Res Int. 2023;30(6):16597-611. [Crossref]  [PubMed] 
  63. Li CW, Wu XL, Zhao XN, Su ZQ, Chen HM, Wang XF, et al. Anti-inflammatory property of the ethanol extract of the root and rhizome of Pogostemon cablin (Blanco) Benth. Sci World J. 2013;2013:434151. [Crossref]  [PubMed]  [PMC] 
  64. Ratnasooriya WD, Jayakody JR, Handunnetti SM, Ratnasooriya CD, Weerasekera KR. Antiinflammatory activity of hot water infusion of nyctanthes arbo-tristis flowers. Indian J Pharm Sci. 2015;77(5):613-9. [Crossref]  [PubMed]  [PMC] 
  65. Hassan S, Sajjad N, Khan SU, Gupta S, Bhat MA, Ali R, et al. Dipsacus inermis wall. modulates inflammation by inhibiting NF-κB pathway: an in vitro and in vivo study. J Ethnopharmacol. 2020;254:112710. [Crossref]  [PubMed] 
  66. Mayovi AA, Alabi AO, Oyibo AO, Joseph OO. Antioedematogenic and anti-inflammatory actions of Phragmanthera incana (Schum) Balle leaf in carrageenan-induced inflammation models in rats. Adv Tradit Med. 2021;21(4):701-11. [Crossref]  [PubMed] 
  67. Ahn JH, Park YL, Song AY, Kim WG, Je CY, Jung DH, et al. Water extract of Artemisia scoparia Waldst. & Kitam suppresses LPS-induced cytokine production and NLRP3 inflammasome activation in macrophages and alleviates carrageenan-induced acute inflammation in mice. J Ethnopharmacol. 2021;268:113606. [Crossref]  [PubMed] 
  68. Ashok P, Koti BC, Thippeswamy AH, Tikare VP, Dabadi P, Viswanathaswamy AH. Evaluation of antiinflammatory activity of centratherum anthelminticum (L) kuntze seed. Indian J Pharm Sci. 2010;72(6):697-703. [Crossref]  [PubMed]  [PMC] 
  69. Alhadidi KM, Ahmed ZA, Numan IT, Hussain SA. Dose-dependent anti-inflammatory effect of silymarin in experimental animal model of chronic inflammation. Afr J Pharm Pharmacol. 2009;3(5):242-7. [Link] 
  70. Ariyo OO, Ajayi AM, Ben Azu B, Aderibigbe AO. Anti-nociceptive and anti-inflammatory activities of ethanol extract and fractions of Morus mesozygia Stapf (Moraceae) leaves and its underlying mechanisms in rodents. J Ethnopharmacol. 2020;259:112934. [Crossref]  [PubMed] 
  71. Nascimento WM, Oliveira JRS, Cunha RX, Gambôa DSR, Silva APS, Lima VLM. Evaluation of the treatment of fever, pain and inflammation with Indigofera suffruticosa Miller Leaves Aqueous Extract. J Ethnopharmacol. 2022;287:114958. [Crossref]  [PubMed] 
  72. Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev. 2016;2016:7432797. [Crossref]  [PubMed]  [PMC] 
  73. Huang SS, Chiu CS, Lin TH, Lee MM, Lee CY, Chang SJ, et al. Antioxidant and anti-inflammatory activities of aqueous extract of Centipeda minima. J Ethnopharmacol. 2013;147(2):395-405. [Crossref]  [PubMed] 
  74. Patro G, Bhattamisra SK, Mohanty BK, Sahoo HB. In vitro and in vivo antioxidant evaluation and estimation of total phenolic, flavonoidal content of mimosa pudica L. Pharmacognosy Res. 2016;8(1):22-8. [Crossref]  [PubMed]  [PMC] 
  75. Agrawal M, Bansal S, Chopra K. Evaluation of the in vitro and in vivo antioxidant potentials of food grade Phycocyanin. J Food Sci Technol. 2021;58(11):4382-90. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 154 - 153
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 197
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 197
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com